Grattan C. Woodson

Zoo Atlanta — United States

Medicine · Health Sciences

13h-index3.2kcitations23works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(17), Bone health and osteoporosis research(16), Bone Metabolism and Diseases(8), Estrogen and related hormone effects(3), Cardiac electrophysiology and arrhythmias(2)

Publications23 total

A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial
Journal of Bone and Mineral Research·2016· 49 citedOpen Access
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial
The Journal of Clinical Endocrinology & Metabolism·2012· 80 citedOpen Access
Denosumab Densitometric Changes Assessed by Quantitative Computed Tomography at the Spine and Hip in Postmenopausal Women With Osteoporosis
Journal of Clinical Densitometry·2012· 32 cited
Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies
Journal of Bone and Mineral Research·2010· 249 citedOpen Access
Denosumab Increased BMD of the Lumbar Spine, Total Hip, Femoral Neck, and Trochanter as Measured by QCT in Postmenopausal Women with Osteoporosis
Journal of Clinical Densitometry·2010
Comparison of bone architecture via micro-ct after long-term treatment with risedronate and alendronate: A cross-sectional study in women with postmenopausal osteoporosis
Bone·2008
Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study
Journal of Bone and Mineral Research·2007· 232 citedOpen Access
Denosumab in Postmenopausal Women With Low Bone Mineral Density
Obstetrical & Gynecological Survey·2006· 21 cited
Denosumab in Postmenopausal Women with Low Bone Mineral Density
New England Journal of Medicine·2006· 1.2k citedOpen Access
Risk factors for osteoporosis
Current Medical Research and Opinion·2004· 13 cited
Abstract #31: Early Effects of Teriparatide in Postmenopausal Women with Osteoporosis
Endocrine Practice·2004
Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms
Clinical Therapeutics·2000· 51 cited
Dual X-Ray Absorptiometry T-Score Concordance and Discordance Between Hip and Spine Measurement Sites
Journal of Clinical Densitometry·2000· 104 cited
Risedronate prevents the first vertebral fracture in at-risk postmenopausal women.
Bone·2000· 1 cited
The rechallenge of patients who previously discontinued alendronate due to upper gastrointestinal symptoms
The American Journal of Gastroenterology·2000
An Interesting Case of Osteomalacia Due to Antacid Use Associated With Stainable Bone Aluminum in a Patient With Normal Renal Function
Bone·1998· 102 cited
Risedronate treatment of postmenopausal women with low bone mass: Preliminary data
Osteoporosis International·1996· 6 cited
Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.
The Journal of Clinical Endocrinology & Metabolism·1994· 48 cited
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
Maturitas·1991· 5 cited
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
New England Journal of Medicine·1990· 956 cited
page 1 of 2Next →

Frequent Co-authors

Paul D. Miller(11), Michael A. Bolognese(7), Michael R. McClung(5), E. Michael Lewiecki(5), Jacques P. Brown(5), David L. Kendler(5), Charles H. Chesnut(3), Pirow Bekker(3), Angelo A. Licata(3), David W. Dempster(3), David A. Hanley(3), Mark P. Ettinger(3), Stanley Cohen(2), Alfred H. Moffett(2), Samuel Lederman(2), Douglas Lain(2), Alan Kivitz(2), Donna Holloway(2), Charlie Zhang(2), Mark Peterson(2)